
BridgeBio Pharma (NASDAQ:BBIO) announced early positive data from the the first two participants dosed in CANaspire clinical study for the treatment of Canavan disease.
CANaspire is a Phase 1/2 open-label study designed to evaluate the safety, tolerability, and pharmacodynamic activity of AAV9 gene therapy candidate, BBP-812, for the treatment of Canavan disease.